InvestorsHub Logo
Followers 12
Posts 2336
Boards Moderated 0
Alias Born 04/20/2006

Re: Andecker post# 13736

Monday, 05/23/2022 10:14:37 AM

Monday, May 23, 2022 10:14:37 AM

Post# of 14947
Waiting to see the news release from Sorrento, lol. The NDA was based on a phase II trial of Abivertinib, so what does that really say. Approval of an NDA is not an easy process and in this case the NDA was not given. Did SORRENTO receive a clinical hold at P2, I do not believe they did. No doubt there is a letter describing the reason for not granting the NDA at P2. Chances of seeing that is slim.
COVISTIX sales...no I do not see that either. The EVP title for Ms. C was a red flag and now the NDA rejection. The question now is what the way is forward, product success, acquisition, RS, BK...it is all on the table, but we have 3 to 4 quarters to get across the finish line or to be finished.
SCILEX is up next and after that...something needs to happen, and will happen for the better or worse, in 2023.
Schlepping... a word I haven't heard in quite a while, but you are most likely correct that they are discussing the color of lipstick to put on this baby.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SRNE News